Key result
Danaparoïd was successfully used for thrombosis prophylaxis in a high-thrombosis-risk pregnant woman with a history of heparin-induced thrombocytopenia and Widal's disease.
Why the study?
Does danaparoid prevent thrombosis in a high-thrombosis-risk pregnant woman with a history of HIT and Widal's disease?
Case Report (n=1)
Does danaparoid prevent thrombosis in a high-thrombosis-risk pregnant woman with a history of HIT and Widal's disease?
Danaparoid may serve as an effective alternative for thromboembolic prophylaxis in pregnant women with a history of heparin-induced thrombocytopenia.
There is no consensus concerning thromboembolic prophylaxis in high-risk pregnant women with a previous history of heparin-induced thrombocytopenia. An alternative anticoagulant therapy is danaparoïd, whereas unfractioned and low-molecular-weight heparin therapy is contraindicated. We report a case of successful thrombosis prophylaxis using danaparoïd in a high-thrombosis-risk pregnant woman with a history of heparin-induced thrombocytopenia during a previous pregnancy and Widal's disease.
No takes yet. Share an insight, caveat, or question.
Macchi et al. (2000) conducted a case report in High-thrombosis-risk pregnancy with history of heparin-induced thrombocytopenia and Widal's disease (n=1). Danaparoïd was evaluated on Successful thrombosis prophylaxis. Danaparoïd was successfully used for thrombosis prophylaxis in a high-thrombosis-risk pregnant woman with a history of heparin-induced thrombocytopenia and Widal's disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: